Printer Friendly

Takeda and Biologics E. enter into vaccines agreement.

M2 EQUITYBITES-June 26, 2017-Takeda and Biologics E. enter into vaccines agreement


Japanese firm Takeda Pharmaceutical Company Limited (TYO: 4502) has entered into a collaborative agreement with Hyderabad-based Biological E. Limited. According to an announcement by Takeda on Monday, it will centre on two licensing agreements that will accelerate the development and delivery of affordable combination vaccines.

Biological E. is set to be responsible for the commercialisation of vaccines in India, China and other low- to middle-income countries which have expansive unmet public health needs.

The vaccines encompassed in the collaboration include Takeda's measles and pertussis vaccines, which have been available in the Japanese market for more than 20 years.

"Access to medicines is one of Takeda's core values, and these agreements align with Takeda's strategic goals to make high-impact contributions to global public health, either alone or through partners," commented Rahul Singhvi, chief operating officer of Takeda's vaccine business unit.

"These two agreements along with our current vaccine pipeline underscore our global commitment to address important infectious diseases across the globe."

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 26, 2017
Previous Article:UAE Ministry of Health and Prevention signs MoU with Lundbeck to improve mental health awareness.
Next Article:Brazilian Firms Vindi, Smartbill Merge to Serve Latin America Payments Markets.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters